Page 40 - PowerPoint Presentation

Sentinel lymph node

biopsy in melanoma

 Recommended for T2-3 tumours (1-

4mm)

 For accurate nodal staging

Positive nodes upstages to stage III

 Survival benefit

Multi-center Selective

Lymphadenectomy Trial II (MSLT-II)

has started since 2004 and is

expected to complete in 9/2022

to provide more answers.

(https://www.clinicaltrials.gov/ct2/

show/NCT00297895)